Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Jan 28, 2022 5:19pm
138 Views
Post# 34373231

RE:RE:Encouraging

RE:RE:Encouraging

Here is an example of an siRNA conjugate developed by academic researchers at Duke that delivers siRNA to prostate cancer by targeting the PSMA antigen.

https://www.qpcrupdate.info/mcnamara-sirna-2006.pdf


qwerty22 wrote:

Seems exciting. I would generally think of this as the expansion of the SORT1 technology that would come after validation of TH1902 in the present trial. After all if they have nothing coming out of this trial it's much harder to get the investment in follow on molecules. Having said that, in the scheme of things, it's a pretty small investment in one scientist and bench fees. So again it looks like they believe that the validation is coming (maybe).

 

scarlet1967 wrote:

 

They are now officially looking for someone to explore siRNA/mRNA opportunities.



Check out this job at Theratechnologies Inc.: Scientist; siRNA Specialist
https://www.linkedin.com/jobs/view/2893910019


 





<< Previous
Bullboard Posts
Next >>